Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

M. L. Donato, A. Aleman, R. E. Champlin, R. M. Saliba, J. T. Wharton, T. W. Burke, D. C. Bodurka, M. W. Bevers, C. F. Levenback, J. K. Wolf, R. C. Bast, R. S. Freedman, C. Ippoliti, M. Brewer, J. L. Gajewski, D. M. Gershenson

    Research output: Contribution to journalArticle

    26 Scopus citations

    Abstract

    The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan-Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

    Original languageEnglish (US)
    Pages (from-to)1219-1224
    Number of pages6
    JournalBone marrow transplantation
    Volume33
    Issue number12
    DOIs
    StatePublished - Jun 1 2004

    Keywords

    • High-dose chemotherapy
    • Ovarian cancer
    • Stem cell transplantation

    ASJC Scopus subject areas

    • Hematology
    • Transplantation

    Fingerprint Dive into the research topics of 'Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Donato, M. L., Aleman, A., Champlin, R. E., Saliba, R. M., Wharton, J. T., Burke, T. W., Bodurka, D. C., Bevers, M. W., Levenback, C. F., Wolf, J. K., Bast, R. C., Freedman, R. S., Ippoliti, C., Brewer, M., Gajewski, J. L., & Gershenson, D. M. (2004). Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone marrow transplantation, 33(12), 1219-1224. https://doi.org/10.1038/sj.bmt.1704473